)
Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Common early side effects include nausea, vomiting, diarrhoea, and reduced appetite, consistent with the GLP-1 receptor agonist class
It has not been submitted for FDA approval, and no US IND/NDA filing has occurred as of mid-2026 Lilly's US development (outside Innovent's China rights) is still in earlier-phase trials
doi: 10.1124/pr.115.011395 2 NauckMAQuastDRWefersJMeierJJ
Understanding Tirzepatide How it Works The dual-agents medication targeting both GIP and GLP-1 receptors results in an increased insulin secretion mechanism and better-than-single-action medications suppress appetite
US$ 29.82
US$ 26.43
US$ 24.10
US$ 24.75
